From: Adherence evaluation of endocrine treatment in breast cancer: methodological aspects
 | Frequency (%) | |
---|---|---|
Age | Median (SD) | 65.00 y (8.3y) |
 | Range | 40-84y |
Marital status | Single | 18 (8.4%) |
 | Partnership, marriage | 135 (63.1%) |
 | Divorced, separated | 28 (13.1%) |
 | Widowed | 33 (15.4%) |
Employment status | Full-time | 16 (7.5%) |
 | Part-time | 16 (7.5%) |
 | Unemployed | 5 (2.1%) |
 | Homemaker | 31 (14.5%) |
 | Retired | 142 (66.4%) |
 | Other | 4 (1.6%) |
Histological classification | Invasive | 226 (93.4%) |
 | In situ | 15 (6.2%) |
 | Missing | 1 (0.4%) |
Grading | Grade I | 35 (14.5%) |
 | Grade II | 176 (72.7%) |
 | Grade III | 10 (4.1%) |
 | Unknown | 21 (8.7%) |
Duration of adjuvant endocrine therapy (months) | Median (SD) | 26.7 (19.1) mo. |
 | Range | 0.7- 89.5 mo. |
Primary surgical treatment | Breast-conserving procedure | 155 (65.7%) |
 | Mastectomy | 81 (34.3%) |
 | Reconstruction | 43 (18.2%) |
Chemotherapy | Â | 41 (16.9%) |
Radiotherapy | Â | 169 (71.3%) |